The best way to heal

  • Description
  • Benefits
  • Indications
  • In Practice
  • FAQs
  • Evidence
  Download product information

Flexible contact layer with TLC-NOSF

Accelerating healing while generating savings

  • Speeds up wound healing(1) and avoids wounds becoming longstanding 
  • Is cost-effective
  • Improves patients’ quality of life (1)

Composition

UrgoStart Contact is a flexible contact layer with TLC-NOSF comprised of:

  • A conformable polyester mesh impregnated with hydrocolloid, petroleum jelly and NOSF particles (Nano-Oligo Saccharide Factor).

 

Mode of action

TLC (Technology Lipido-Colloid) combined with NOSF (Nano-Oligo Saccharide Factor) is a patented innovative technology which in contact with wound exudate forms a gel and creates a moist environment enabling the key cells involved in the repair process (fibroblasts, keratinocyrtes, macrophages) to exert their action.

TLC-NOSF interacts with the wound micro-environment of the wound by preventing the detrimental effect of Matrix Metallo Proteases (MMPs) which in excess in chronic wounds creates a continuous degradation of the extra-cellular matrix. TLC-NOSF restores balance in the wound bed so granulation of chronic wounds can occur. UrgoStart Contact thereby promotes faster wound healing.

TLC NOSF Technology

* Studies on pathophysiological mechanisms in healing have demonstrated the essential role of proteases (MMPs) in the persistence of inflammatory responses and the slowing of wound healing (2, 3, 4, 5). Proteases are enzymes that participate in the physiological wound cleansing process; they help set the stage for healing. However, when subcutaneous tissue is ischaemic, for example in arterial disease or diabetes, the presence of proteases becomes excessive, causing persistent inflammation and dermal destruction (2). This excess of proteases has been observed in leg, pressure and diabetic foot ulcers, the three major types of chronic wounds (2,3,4,5).
 
(1) Meaume S, et al.A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair and Regeneration 2012 (July/August);Vol 20:500-511.
(2) Kirsner et al. Wounds, 2002,vol 13, N°3, May/june,
(3) R Lobmann. Diabetologia 2002 ; 45:1011–1016
(4) Y Liu. Diabetes Care 2009; 32:117–9
(5) A Moore. Wound Rep Regen 2009;17:832-39

 


This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Benefits for the wound

  • Faster healing
  • Avoids wounds becoming longstanding with associated risks of complications
  • Neutralisation of excess proteases
  • Moist wound healing
  • Fibroblast proliferation
  • No adherence to the wound (no damage of newly formed tissue)
  • Can be left in place for up to 7 days – fewer dressing changes reducing healing disturbance
  • High conformability to the wound bed

benefits-for-professionnalBenefits for health professionals

  • Faster wound healing
  • Avoids wounds becoming longstanding with associated risks of complications
  • Clinically proven in a Randomised Controlled Trial
  • Cost effective treatment
  • Improves patients’ quality of life: less anxiety, less depression, less pain
  • Easy to apply
  • Stays in place when applied
  • Easy to remove with pain-free dressing changes
  • Very conformable
  • Can be used under compression
  • Can be used in cavity wounds
  • Can be left in place for up to 7 days – fewer dressing changes

benefits-for-patientBenefits for patients

  • Faster recovery
  • Avoids wounds becoming longstanding with associated risks of complications
  • Improvement of patients’ quality of life
  • No adherence to the wound: pain-free dressing changes
  • Well tolerated
  • Very conformable (stretchable to move with the body) and comfortable
  • Can be left in place for up to 7 days – fewer dressing changes

UrgoStart Contact is indicated for non to low exuding chronic wounds (leg ulcers, pressure ulcers, diabetic foot ulcers, longstanding acute wounds).

Flexible and very conformable, UrgoStart Contact is especially suitable for lining cavity or awkwardly placed wounds and for wicking deep wounds.

Contraindications

In order not to delay any optimal treatment, UrgoStart Contact is contraindicated in wounds such as cancerous wounds or fistula wounds which may reveal a deep abscess.

Do not use if there is a known sensitivity to UrgoStart Contact.

mode_emploi_urgostart_contactInstructions for use

  • Clean the wound as per local protocol and rinse with normal saline.
  • If an antiseptic is first used, rinse the wound thoroughly with saline solution before applying UrgoStart Contact.
  • UrgoStart Contact can be cut using sterile equipment to fit the dressing size to the wound if necessary.
  • Using the tabs, remove the protective film.
  • Apply UrgoStart Contact to the wound.
  • Cover UrgoStart Contact with a secondary dressing suitable for the location and level of wound exudate.
  • Secure the dressing in place with a suitable bandage or an adhesive tape. Apply a compression bandage when prescribed.
  • UrgoStart Contact dressing may be changed every 2 to 4 days, and left in place up to 7 days depending on the level of exudate and the clinical condition of the wound.
  • The recommended treatment duration is a minimum of 8 weeks until wound healing.

Precautions for use

  • As UrgoStart Contact can adhere to surgical gloves (latex), it is recommended that gloves should be moistened with normal saline to facilitate handling of the dressing.
  • If signs of critical colonisation are present, suitable treatment is recommended before using UrgoStart Contact.
  • In case of an atypical ulcer presenting induration or overgranulation, UrgoStart Contact should only be used after checking the absence of wound-related malignancy in order not delay the diagnosis.
  • The action of the product on the healing process may possibly cause stinging or painful sensations at the start of the treatment with UrgoStart Contact. This rarely warrants suspension of treatment.
  • In case of deep wounds and fistula wounds, a section of the UrgoStart Contact dressing should be left visible to enable easy removal.
  • In the absence of clinical data as a first line treatment in acute wounds, and in the treatment of Epidermolysis bullosa (even for longstanding lesions), it is not recommended to use UrgoStart Contact.
  • Discard any unused parts of the dressing.
  • Check that the sterility protector is intact before use.
  • Single-use, individual and sterile dressing: re-using a single-use product may lead to risks of infection.
  • Do not re-sterilise the dressing.UrgoStart Contact 10x10

Sizes available

  • 5×7 cm
  • 10×10 cm; 10×12 cm; 13×12 cm
  • 15×15 cm; 15×20 cm

 

 


This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Product

What is UrgoStart Contact?

UrgoStart Contact is an ultra-flexible contact layer with TLC-NOSF.

How does UrgoStart Contact work?

TLC (Technology Lipido-Colloid) combined with NOSF (Nano-Oligo Saccharide Factor) is a patented innovative technology which in contact with wound exudate forms a gel and creates a moist environment enabling the key cells involved in the repair process (fibroblasts, keratinocyrtes, macrophages) to exert their action.

TLC-NOSF interacts with the wound micro-environment of the wound by preventing the detrimental effect of Matrix Metallo Proteases (MMPs) which in excess in chronic wounds creates a continuous degradation of the extra-cellular matrix. TLC-NOSF restores balance in the wound bed so granulation of chronic wounds can occur. UrgoStart Contact thereby promotes faster wound healing.

Why do you say that UrgoStart Contact is cost-effective?

Due to improved healing rates, UrgoStart Contact reduces overall treatment time, and therefore the number of nurse visits and the associated costs.

Indications

When should I use UrgoStart Contact?

UrgoStart Contact is indicated for non to low exuding chronic wounds (leg ulcers, pressure ulcers, diabetic foot ulcers, longstanding acute wounds…).
Flexible and very comformable, UrgoStart Contact is especially suitable for lining cavity or awkwardly placed wounds and for wicking deep wounds.

Can I use UrgoStart Contact during the epithelialisation stage?

Yes.

Can I use UrgoStart Contact in desloughing stage?

For desloughing, UrgoClean is recommended as the best option.

Can I use UrgoStart Contact on infected wounds?

In the case of an infected wound, an antibacterial dressing should be used before using UrgoStart Contact.

What are the contraindications of UrgoStart Contact?

In order not to delay any optimal treatment, UrgoStart Contact is contraindicated in wounds such as cancerous wounds or fistula wounds which may reveal a deep abscess.

Do not use if there is a known sensitivity to UrgoStart Contact.

Use

UrgoStart Contact can adhere to gloves. How should I avoid this?

It is recommended to moisten the gloves with normal saline and to use the protective wings to facilitate application.

cutting-dressing-guide

Cutting Guide

Can I cut UrgoStart Contact?

Yes.

How can I secure UrgoStart Contact?

Cover UrgoStart Contact with a secondary dressing suitable for the location and level of wound exudate. Secure the dressing in place with a suitable bandage, adhesive tape, or apply a compression bandage when prescribed.

Can I use UrgoStart Contact under compression?

Yes.

When should I change UrgoStart Contact?

UrgoStart Contact should be changed every 2 to 4 days (up to 7 days) depending on the level of exudate and the clinical condition of the wound.

The wound seems larger after treatment with UrgoStart Contact. Is this to be expected?

It has been demonstrated that the wound may initially appear larger after treatment with UrgoStart Contact, before reducing in size. Continuing treatment with UrgoStart Contact is essential to promote faster healing.

My patient complains with pain/stinging, is this to be expected?

In some cases, this has been noted during the initial stages. However, if the patient is able to tolerate it, continued treatment with UrgoStart Contact is essential to promote faster healing.

Evidence

What evidence do you have?

The efficacy of TLC-NOSF has been clinically proven in:

  • A Double blind Randomised Controlled Trial demonstrating that it heals twice as fast as a neutral foam dressing (with the foam version - UrgoStart) (1)
  • A randomized Controlled Trial (with the contact layer version – UrgoStart Contact) (2)
  • Observational studies
  • Several clinical studies on leg ulcers, pressure ulcers and diabetic foot ulcers

What is a Randomised Controlled Trial?

A Randomised Controlled Trial is the most superior level of evidence required by Heath Authorities.

“Randomised” means that patients are chosen at random to be included in either of the two groups.

“Controlled” means that the treatment is tested against another treatment that has proven its efficacy.

(1) Meaume S, et al.A randomized, controlled, double-blind prospective trial with a Lipido-Colloid Technology-Nano-OligoSaccharide Factor wound dressing in the local management of venous leg ulcers. Wound Repair and Regeneration 2012 (July/August);Vol 20:500-511.
(2) Schmutz J-L, Meaume S, Fays S, Ourabah Z, Guillot B, Thirion V, Collier M, Barrett S, Smith J,
Bohbot S, Dompmartin A, et al. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. Int Wound J 2008;5:172–182.

UrgoStart range has been evaluated in numerous European clinical studies involving patients with different types of wounds, in particular leg ulcers, pressure ulcers and diabetic foot ulcers.

Its clinical efficacy has been demonstrated for venous or mixed predominantly venous ulcers in two comparative controlled clinical studies, one vs Promogran and another, the Challenge study, vs a neutral dressing.

 

JWC_21_3_142_147_Richard_web Urgo_Review_resize_A4_web  

Management of diabetic foot ulcers with a TLC-NOSF wound dressing

Supporting evidence-based practice: a clinical review of TLC technology  
Download Download  

Evaluation of the nanooligosaccharide factor lipidocolloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial

Schmutz JL; et al, International Wound Journal, Vol 5 No 2, 2008.

abstract_urgostart_contact

Last update : November 23, 2017